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C E L L  B I O L O G Y
PLK1 regulates the PrimPol damage tolerance  
pathway during the cell cycle
Laura J. Bailey1†, Rebecca Teague1†, Peter Kolesar1‡, Lewis J. Bainbridge1,  
Howard D. Lindsay2, Aidan J. Doherty1*
Replication stress and DNA damage stall replication forks and impede genome synthesis. During S phase, damage 
tolerance pathways allow lesion bypass to ensure efficient genome duplication. One such pathway is repriming, 
mediated by Primase-Polymerase (PrimPol) in human cells. However, the mechanisms by which PrimPol is regu-
lated are poorly understood. Here, we demonstrate that PrimPol is phosphorylated by Polo-like kinase 1 (PLK1) 
at a conserved residue between PrimPol’s RPA binding motifs. This phosphorylation is differentially modified 
throughout the cell cycle, which prevents aberrant recruitment of PrimPol to chromatin. Phosphorylation can also 
be delayed and reversed in response to replication stress. The absence of PLK1-dependent regulation of PrimPol 
induces phenotypes including chromosome breaks, micronuclei, and decreased survival after treatment with 
camptothecin, olaparib, and UV-C. Together, these findings establish that deregulated repriming leads to genomic 
instability, highlighting the importance of regulating this damage tolerance pathway following fork stalling and 
throughout the cell cycle.
INTRODUCTION
The DNA replication machinery regularly encounters obstacles that 
slow or stall its progression. The causes of replicase stalling are 
varied and include DNA lesions and structures, nucleotide deple-
tion, and other forms of genotoxic stress (1). To complete replica-
tion, cells must bypass such impediments, as unresolved forks are 
susceptible to degradation and may induce double-strand breaks. 
Cells have evolved several DNA damage tolerance (DDT) pathways 
to maintain ongoing replication under perturbed conditions, whose 
usage is dependent on the environment, type of blockage, and 
available resources.
One such DDT pathway involves repriming DNA synthesis 
downstream of obstacles to enable stalled replication to resume. 
Repriming in human cells is dependent on Primase-Polymerase 
(PrimPol), an enzyme involved in the maintenance of nuclear and 
mitochondrial DNA replication (2, 3). PrimPol can reprime DNA 
synthesis on the leading strand after the fork encounters stalling 
lesions, such as cyclopyrimidine dimers and structured DNA 
(e.g., G4 quadruplexes), as well as chain terminators (4–7). PrimPol 
can also perform translesion synthesis (TLS) polymerase, replicating 
across DNA lesions (e.g., 8-oxoG and 6-4 photoproducts) that stall 
replicative polymerases (6, 7).
Specialized DNA polymerases, such as Pol Eta (), can also 
perform TLS (8, 9). This allows for continuous replication and 
lesion bypass at the expense of fidelity (10). Other DDT pathways, 
involving fork reversal, provide more error-free bypass mechanisms 
(11). As many DDT pathways are available during DNA replication, 
it is essential that cells use the optimal restart pathway to efficiently 
reinitiate genome synthesis.
The availability of alternative overlapping DDT pathways means 
that, despite its importance in maintaining active replication forks, 
cells lacking PrimPol are viable and grow normally. However, these 
cells have delayed recovery times after ultraviolet C (UV-C) damage 
and hallmarks of replication stress, such as increased micronuclei 
and elevated mutation frequencies (6, 12, 13). These phenotypes are 
further exacerbated when other DDT pathways are disrupted, such 
as in the absence of Pol , where PrimPol-null cells exhibit an overt 
UV-C sensitivity (4, 6, 12). Recent studies have also shown that in 
the absence of HLTF, an enzyme involved in fork reversal, PrimPol- 
mediated repriming or TLS is used to rescue stalled forks (14). 
Similarly, in the absence of CARM1/PRMT4, implicated in the 
stabilization of reversed forks, PrimPol and TLS are both used to 
restart replication forks (15). PrimPol also plays a role in DDT 
when cells lack BRCA1, with PrimPol protein levels increasing after 
multiple cisplatin doses, leading to suppressed fork reversal (16).
While PrimPol can operate when other pathways are unavailable, 
it is unknown how PrimPol is prevented from acting when reprim-
ing is undesirable. PrimPol must be tightly regulated during DNA 
replication to avoid aberrant repriming, fork speeding, and chro-
mosomal breaks (15), and such regulation would therefore need to 
be dynamic to respond to DNA damage or changes in DDT 
pathway availability. While recent studies have shown that PrimPol 
protein levels are tightly controlled by ATR activity and regulated 
by WRNIP1 levels (16–18), there is currently no evidence for a 
more responsive mode of regulation.
Posttranslational modifications (PTMs) provide a dynamic and 
reversible form of regulation that is known to play roles in regulating 
DDT pathways. TLS polymerases, such as Pol , are highly regulated 
by PTMs, such as phosphorylation, ubiquitination, and SUMOylation 
(19–22). To control phosphorylation, cells use a number of specific 
kinases and phosphatases to regulate progression through the cell 
cycle and the cell’s response to replication stress. One such kinase is 
Polo-like kinase 1 (PLK1), which has a critical role in mitotic 
progression and has also been implicated in the DNA damage 
response (23–25). PLK1 regulates many DNA damage response 
proteins, including Rad51, BRCA2, and MRE11 (26–28). PLK1 itself 
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is also regulated by a defined methylation/phosphorylation switch, 
important for the timely removal of RPA2 (Replication Protein A2) 
and Rad51 from DNA damage sites (29).
Here, we report that PrimPol is phosphorylated by PLK1 on a 
highly conserved serine residue, located between two RPA binding 
sites at its C terminus. Phosphorylation by PLK1 occurs at the end 
of S phase, although it can be modulated in response to high levels 
of replication stress, such as that induced by the poly(ADP-ribose) 
polymerase (PARP) inhibitor olaparib or the topoisomerase poison 
camptothecin. Deregulation of this PLK1-dependent phos-
phorylation leads to damage sensitivity and the onset of cellular 
phenotypes associated with genomic instability, including micro-
nuclei, chromosome breaks, and mitotic defects. Together, these 
findings establish that PLK1 provides regulatory control over PrimPol 
during the cell cycle to restrict its activity outside of S phase, where it is 
required for restarting stalled forks to ensure that DNA replication 
proceeds in a timely and efficient manner.
RESULTS
PrimPol is phosphorylated at a conserved serine located 
between the RPA binding motifs
Despite recent progress, little is known about how PrimPol’s activity 
and recruitment are regulated throughout the cell cycle. Given that 
its interaction with RPA is requisite for PrimPol’s functionality at 
stalled forks, PTMs in the C terminus may play a role in its regula-
tion. We carried out mass spectrometry analysis on Flag-tagged 
PrimPol from human cells to detect potential modifications that 
may play roles in regulating its activity. We identified a number of 
phosphorylation sites (fig. S1A), including a serine residue (S538) 
located between the two RPA binding motifs (RBMs) in human 
PrimPol. We also identified phosphorylation of a homologous 
residue on the C terminus of Xenopus laevis PrimPol and found 
that this modification is conserved with the duplication of the RBM B 
(fig. S1A). As this residue is also highly conserved in other eukaryotes 
(Fig.  1A), we hypothesized that it may play a role in regulating 
PrimPol. To study the significance of this phosphorylation in human 
cells, we generated a phospho-specific antibody, raised against a 
peptide containing phosphorylated S538 (P-S538). To confirm this 
antibody’s specificity, we tested it against whole-cell extracts from 
human embryonic kidney (HEK) 293 cells expressing PrimPol or mu-
tants PrimPolS538A and PrimPolS538E (Fig. 1B). While S538 phosphoryl-
ation was observed for wild-type (WT) protein, no binding was 
observed when S538 was mutated. In addition, antibody binding was 
also lost when cell lysate was treated with  phosphatase (fig. S1B).
Disruption of S538 phosphorylation affects cell growth 
and genome stability
To analyze the significance of S538 phosphorylation, we examined 
the effects that disrupting this modification had in cultured human 
A B C D
E F G
Fig. 1. PrimPol is modified by phosphorylation at S538, and loss of this causes genomic instability. (A) Alignment of the C-terminal region of PrimPol (PP) containing 
the RPA binding domain (RBD). Hs, Homo sapien (human); Tt, Tursiops truncatus (Atlantic bottle-nosed dolphin); Ts, Tarsius syrichta (Philippine tarsier); Hg, Heterocephalus 
glaber (naked mole rat); Cp, Cavia porcellus (guinea pig); Mm, Mus musculus (mouse); Md, Monodelphis domestica (gray short-tailed opossum); Gg, Gallus gallus (chicken); 
Xt, Xenopus tropicalis (Western clawed frog); Ap, Anas platyrhynchos (Northern mallard); Ci, Ciona intestinalis (vase tunicate); AEP, Archaeao-Eukaryotic Primase. (B) Protein 
phosphorylation was examined in whole-cell lysate from HEK293 cells where PrimPol was expressed by addition of doxycycline for 24 hours, analyzed by Western blotting. 
(C) Plating efficiency of different cell lines expressing PrimPol variants compared to no-doxycycline controls. (D) PP-1 cells expressing PrimPol, PrimPolS538A, or PrimPolS538E 
were collected, and detergent- resistant chromatin fractions were separated from soluble proteins before being separated by Western blot. (E) Quantification of cells with 
one or more micronuclei 48 hours after PrimPol expression. (F) PrimPol was expressed for 96 hours in HEK293 cells before being stalled in mitosis with nocodazole. 
Chromosomes were spread, and those containing one or more chromosome with a break were quantified as a percentage of the population. (G) To analyze sister chromatid 
exchanges, cells were grown in 10 M BrdU for 48 hours before being blocked in mitosis. Cells were spread and stained with Hoescht and Geimsa, and the number of 
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cells. We first generated several PrimPol−/− clones in a Flp-In 
HEK293 T-REx cell line, denoted PP-1-3. These cells all carried 
biallelic PrimPol deletions, which lead to downstream gene disrup-
tion, with no observed PrimPol protein production (fig. S1C). PP 
cells exhibited phenotypes similar to those observed previously in 
MRC5 PrimPol−/− cells, namely, normal growth and no UV-C 
sensitivity, but delayed cell cycle recovery after UV damage (fig. S1, 
D to G) (12). N-terminal FLAG-tagged PrimPol or PrimPol con-
taining S538 mutations was stably introduced into the Flp-In T-REx 
site in these cells and expressed using doxycycline (Fig. 1B and fig. 
S2A) (30). To analyze any defect arising from the expression of 
mutant PrimPol, we used colony formation assays in the presence 
or absence of doxycycline to assess plating efficiency. While PrimPol 
and PrimPolS538E expression had no effect on plating efficiency, 
PrimPolS538A caused a significant decrease in colony formation 
(Fig. 1C). In addition, while expression of PrimPol had little effect 
on growth rates, PrimPolS538A caused a small but significant in-
crease in doubling times, suggesting that this modification may play 
a role in PrimPol’s ability to maintain cell cycle progression or cell 
viability (fig. S2B). We also observed a similar effect on plating 
efficiency when we expressed PrimPolS538A in parental cells carry-
ing endogenous PrimPol protein, indicating that this mutation has 
a dominant negative effect (Fig. 1C). However, we found no signifi-
cant changes in cell cycle populations 48 hours after protein induc-
tion (fig. S2C).
As S538 resides between the RBMs, it may regulate PrimPol’s 
interaction with RPA and thus its recruitment and retention on 
single-stranded DNA (ssDNA). However, when we analyzed the 
binding of the C-terminal region of WT or mutant PrimPol with 
RPA70N by analytical gel filtration, we observed no overt changes 
in the interactions between PrimPol and RPA in vitro (fig. S3A). 
We also found no changes in PrimPol and RPA interaction in vivo 
after mutation of the S538 residue when analyzed by immuno-
precipitation (fig. S3B). In addition, mutation of S538 did not affect 
PrimPol’s chromatin association in vivo (Fig. 1D). Notably, bio-
chemical analysis also showed that neither PrimPolS538A nor 
PrimPolS538E altered primase or polymerase activities or fidelity 
in vitro (fig. S3, C and D).
To understand the impact of mutating the S538 phosphorylation 
site, we examined markers of genomic instability. Cells expressing 
PrimPolS538A showed an increase in micronuclei under unperturbed 
conditions (Fig. 1E) and substantially more chromosomal breaks 
(Fig. 1F). As with PrimPol−/− MRC5 cells, PP cells exhibited 
increased sister chromatid exchanges (SCEs) that could be rescued 
by expression of PrimPol or PrimPolS538E but not PrimPolS538A 
(Fig. 1G) (12). Together, these results indicate that PrimPolS538A 
expression leads to an increase in genomic instability.
PrimPolS538A decreases cell viability after  
UV-C–induced DNA damage
As PrimPol is required for repriming DNA replication after fork 
stalling lesions and structures, we examined the role of S538 phos-
phorylation in maintaining DNA replication and cell viability after 
DNA damage (4, 5, 7). After treatment with UV-C, we observed a 
significant increase in damage sensitivity in cells expressing the 
phospho-null mutant (PrimPolS538A) compared to PP cells (Fig. 2A), 
establishing that expressing PrimPolS538A is more harmful than the 
absence of PrimPol. To confirm that this was not an artifact of an indi-
vidual clone, we carried out UV-C survival assays on three independent 
PrimPol knockout clones complemented with PrimPolS538A and 
obtained consistent results (fig. S4A). In addition, we observed a 
decrease in UV-C survival when expressing PrimPolS538A in parental 
cells, which also have endogenous protein, indicating that endoge-
nous levels of PrimPol are not able to overcome the toxicity of 
PrimPolS538A (fig. S4A). Moreover, cells expressing PrimPolS538A 
also showed a sensitivity to the cross-linking agent cisplatin (Fig. 2A 
and fig. S4A). As previously reported, PrimPol−/− cells exhibit de-
layed recovery after UV-C (12); we therefore measured the ability of 
the different PrimPol proteins to complement this defect. As in 
MRC5 PrimPol−/− cells, we observed that expression of PrimPol 
and PrimPolS538E decreased the delay in recovery time 24 hours 
after UV-C damage. While cells expressing PrimPolS538A showed 
less delay than PP cells, there was an increase in late S-G2-M 
stalling (Fig.  2B and fig. S4B). We also examined hallmarks of 
genome instability and found a significant increase in micronuclei 
after UV-C damage in cells expressing PrimPolS538A, compared to 
those expressing PrimPol or PrimPolS538E (Fig. 2C and fig. S4C). To 
confirm that PrimPolS538A toxicity was not specific to HEK293 cells, 
we expressed PrimPol in RPE1 cells using a Sleeping Beauty trans-
poson expression system (fig. S4D) (31). We found that PrimPolS538A 
expression caused a similar decrease in survival after UV-C damage, 
along with hallmarks of genomic instability, such as increased 
micronuclei both with and without UV-C damage (fig. S4, E and F).
In asynchronous cells damaged with UV-C (6 J/m2), there was 
no detectable difference in the amount of mutant PrimPol bound to 
chromatin, compared to PrimPol (fig. S5A). To look more directly 
at the effects of PrimPolS538A at the replication fork, we used a DNA 
fiber assay to analyze ongoing replication after UV damage. Despite 
the increased UV-C sensitivity, both PrimPolS538A and PrimPolS538E 
had minimal effect on fork stalling (Fig. 2D) This suggests that the 
genotoxic effects of PrimPolS538A may be initiated outside of S phase 
replication.
In addition, we found that PrimPolS538A expression caused a 
decrease in replication fork speed under undamaged conditions 
(Fig. 2E and fig. S5B). We observed a small but significant increase 
in replication fork speeds with PrimPolS538E expression, suggesting 
that this mutant is also capable of causing changes in fork progression, 
potentially through alteration of pathway choice at stalled or slowed 
forks (Fig. 2E). This was also observed in parental cells containing 
endogenous PrimPol (fig. S5B). To examine whether PrimPol’s activity 
was inhibited after loss of phosphorylation, we looked at the restart 
of stalled forks after HU or camptothecin treatment and identified 
a decrease in fork restart in the absence of PrimPol. However, 
mutation of S538 did not affect the ability of the protein to comple-
ment this, confirming that, as observed in vitro, the protein remains 
functional in the absence of S538 phosphorylation (fig. S5C).
PrimPolS538A-induced genotoxicity is rescued by 
mutation of RBMs
To confirm whether PrimPolS538A’s phenotype was due directly to 
its activity on DNA, we investigated whether impairing PrimPol’s 
recruitment to chromatin, by mutation of PrimPol’s RBMs, could 
abolish these phenotypes. RBM-A and RBM-B, the two motifs 
responsible for RPA association and therefore recruitment to ssDNA, 
were mutated to generate PrimPolRAB in the presence or absence of the 
S538 mutations (fig. S5D) (30). When expressed alone in PP cells, 
PrimPolRAB had little effect on UV-C survival and rescued PrimPolS538A’s 
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both RPA binding sites (PrimPolRAB) completely reversed the genomic 
instability phenotypes observed with PrimPolS538A, evident by no 
increase in chromosome breaks or micronuclei (Fig. 2G and fig. S5F). 
Together, these findings establish that the genotoxicity induced by 
PrimPolS538A requires PrimPol’s RPA-dependent interaction with 
chromatin.
PrimPolS538A causes sensitivity to olaparib and camptothecin
Recent studies have shown that repriming and fork reversal are 
distinct DDT mechanisms that rescue stalled replication forks. 
Changes in the levels of fork reversal proteins, such as HLTF and 
PARP, have been suggested to alter the balance between these path-
ways and therefore the requirement for PrimPol following stalling 
(14, 15). Therefore, we used the drug olaparib to inhibit PARP and 
determine whether the S538A mutation affected the availability of 
PrimPol for repriming at stalled forks. When we examined colony 
formation in the presence of low doses of olaparib, we observed that 
expression of PrimPolS538A caused a significant increase in sensitivity, 
similar to that observed with other damaging agents (Fig. 3A and 
fig. S6A). However, in addition to affecting the availability of the 
fork reversal pathway, PARP is also used in the resolution of single- 
stranded and double-stranded breaks (SSBs and DSBs); it therefore 
follows that the use of olaparib leads to an increase in SSBs and 
DSBs (32, 33). We investigated this possibility by using the Top1 
poison camptothecin, which has been shown to cause an increase in 
SSBs (34). We observed that, while little sensitivity was evident in 
cells lacking PrimPol, cells expressing PrimPolS538A showed a sig-
nificant decrease in cell survival after the addition of camptothecin 
(Fig. 3A and fig. S6B). These combined sensitivities suggest that this 
is due largely to an increase in breaks and fork stalling itself rather 
than the loss of fork reversal, as this is not affected by camptothecin 
treatment.
We then inspected for other signs of genomic instability and 
stress after treatment with olaparib or camptothecin and again 
found an increase in micronuclei 48 hours after treatment only in 
cells expressing PrimPolS538A (Fig. 3B and fig. S6C). We also observed 
a similar increase in mitotic cells showing abnormalities, such as 
lagging or misaligned chromosomes (Fig. 3C and fig. S6D). In addi-
tion, we noted a significant increase in chromosomes with breaks in 
cells expressing PrimPolS538A, 48  hours after treatment with 
camptothecin or olaparib (Fig. 3D and fig. S6E).
A small change in cell cycle population was observed after olaparib 
treatment, with cells expressing PrimPolS538A stalling in G2-M more 
compared to cells expressing PrimPol or PrimPolS538E (Fig. 3E and 
fig. S6F). As olaparib treatment causes an increase in replication 
speed (35), we investigated whether PrimPol may be involved in this 
process. While fork speeds increased after olaparib treatment, only 
minor differences were observed in cells expressing PrimPolS538A, 
suggesting that S538 phosphorylation does not play a significant 


























































































































































Fig. 2. Loss of PrimPol S538 phosphorylation affects genomic stability after UV-C damage and is dependent on RPA interaction. (A) Damage sensitivity was measured 
by colony survival after increasing doses of UV-C (left) or cisplatin (right). (B) Quantification of cell cycle recovery after damage was measured by flow cytometry, using 
EdU and PI labeling 24 hours after treatment with 5 J/m2 UV-C, images shown in fig. S4B. (C) Cells with one or more micronuclei were counted 48 hours after 5 J/m2 UV-C 
treatment. (D) CldU/IdU ratios show replication changes after a pulse of 20 J/m2 UV-C was given between labels. (E) Undamaged replication fork speeds were measured 
in the different cell lines at least 16 hours after PrimPol expression by labeling cells consecutively with CldU and IdU. (F) UV sensitivity was analyzed by colony survival in 
PP-1 cells expressing RAB mutated forms of PrimPol also carrying the 538 mutations. (G) The effect of loss of PrimPol’s RPA interaction in micronuclei formation was 
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similar to other studies, where no changes in fiber length were 
observed in the absence of PrimPol after olaparib treatment (15). 
Camptothecin is known to cause fork stalling due to DNA torsional 
restraint (36). However, although we observed an increase in CldU 
(5-chloro-2′-deoxyuridine)/IdU (5-Iodo-2′-deoxyuridine) after addi-
tion of 50 nM camptothecin with the second label compared to 
untreated cells, no additional sensitivity was observed in cells ex-
pressing PrimPolS538A (Fig. 3F). Again, this confirms that changes 
in S538 phosphorylation do not significantly affect its role during 
replication perturbation in S phase and support an effect in G2-M.
Mutation of the Zn finger significantly rescues cellular 
defects caused by PrimPolS538A
As our data suggest that the S538A mutation may only have very 
minor effects during unperturbed S phase, we next examined 
whether the phenotypes induced by expression of PrimPolS538A 
were dependent on PrimPol’s primase activity. PrimPol's zinc 
finger (ZF) is required for its primase function and may be important 
for stabilization of the incoming nucleotide, primer translocation, 
and extension (7, 37). Therefore, to further investigate the cause of 
PrimPolS538A-induced cell toxicity, we generated a disruptive ZF 
mutant (C419A, H426A, hereafter PrimPolZF) in the PrimPolS538A 
background (fig. S7A). Expression of PrimPolZF alone did not alter 
plating efficiency, but mutation of the ZF rescued the plating defi-
ciency observed in PrimPolS538A (fig. S7B). Expression of PrimPolZF 
also caused a small decrease in survival after treatment with UV-C, 
olaparib, camptothecin, or cisplatin, suggesting that its primase 
activity is required for restart after such damage (Fig.  4A). The 
combined PrimPolZF, S538A mutant was able to partially rescue the 
S538A-induced decrease in survival after damage but was still less 
viable than PP or PrimPolZF-expressing cells. In addition, PrimPolZF 
was able to largely rescue the increase in chromosomal breaks, 
micronuclei, and abnormal mitotic cells observed after expression of 
PrimPolS538A in both damaged and undamaged cells (Fig. 4, B to D, 
and fig. S7, C to E). However, although levels of micronuclei and 
breaks were significantly lower, they were still consistently higher in 
PrimPolZF, S538A-expressing lines compared with those expressing 
PrimPol. Although substantial loss of genomic instability was 
observed after the addition of PrimPolZF, we noted that PrimPol, 
PrimPolZF, and PrimPolZF S538A all proficiently bound chromatin in 
undamaged cells and cells damaged by UV-C, suggesting that 
recruitment is maintained (fig. S7F).
S538 is phosphorylated by PLK1 in human cells
As ablation of PrimPol S538 phosphorylation clearly has significant 
effects on cellular viability, it appears likely that this modification is 
tightly regulated. To identify the kinase responsible for this phos-
phorylation, we analyzed the sequence motifs around S538 using 
the Eukaryotic Linear Motif database (38) and identified that it 
resides within a signature motif characteristic of a PLK1 site (39, 40). 
This PLK1 motif is also highly conserved in PrimPol across a 
diverse range of higher eukaryotes (Fig. 5A). To determine whether 
the proposed motif containing S538 represents a bona fide PLK1 
phosphorylation site, we purified recombinant PrimPol and per-
formed kinase assays by incubating it with PLK1 and adenosine 
5′-triphosphate (ATP). Using the P-S538–specific antibody, we 
showed that PrimPol, but not PrimPolS538A, was specifically 
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Fig. 3. Cells expressing PrimPolS538A are sensitive to genotoxic agents camptothecin and olaparib. (A) Sensitivity to olaparib (left) or camptothecin (CPT) (right) was 
measured by colony survival approximately 10 days after the addition of drugs. Changes in levels of micronuclei (B) or cells undergoing abnormal mitotic segregation 
(C) were analyzed 48 hours after treatment with camptothecin or olaparib. (D) Chromosome breaks were analyzed 48 hours after treatment with olaparib or camptothecin. 
(E) Effects of olaparib and camptothecin were quantified after 48 hours by flow cytometry; see images in fig. S6F. (F) Effects of olaparib and camptothecin on replication 
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To confirm whether this residue was also modified by PLK1 
in vivo, we used the PLK-specific inhibitor BI2536 (41). Addition of 
BI2536 resulted in an absence of S538 phosphorylation, as identi-
fied using the phospho-specific antibody (Fig. 5C). To verify that 
S538 is specifically phosphorylated by PLK1 in cells, we used RPE1 
PLK1-as cells (42). These cells contain a mutant form of PLK1, 
which can be inactivated using an ATP analog. Cells were stably 
transfected to express PrimPol before treatment with the ATP analog 
3-MBPP1 to inactivate PLK1. In the absence of active PLK1, S538 
phosphorylation was not detected, establishing a specific role for 
PLK1 kinase in phosphorylating PrimPol (Fig. 5C).
Phosphorylation of PrimPol S538 is cell cycle regulated
PLK1 activity changes markedly throughout the cell cycle (43–45). 
Therefore, we examined PrimPol’s S538 phosphorylation levels 
across the cell cycle using thymidine synchronization. Phosphoryl-
ation of S538 was lost in cells synchronized at the G1-S border. 
Phosphorylation was then detectable by late S phase, reaching a 
peak in G2 (Fig. 5D). This phosphorylation was retained through-
out mitosis before decreasing in G1. The same distribution of S538 
phosphorylation was also observed in RPE1 cells across the cell cycle 
(fig. S8A). This pattern of phosphorylation matched that of known 
PLK1 substrates, such as TCTP (Fig. 5D) (46). This establishes that 
S538 phosphorylation is tightly regulated across the cell cycle, 
which suggests that it may be used to regulate PrimPol during 
different cell cycle stages.
To confirm the importance of PLK1 phosphorylation in the 
regulation of PrimPol activity in vivo, we again used the PLK1 
inhibitor BI2536 (41). Cells were synchronized using a thymidine 
block, stalling cells at the G1-S border. Cells were then released into 
media containing nocodazole, and additionally containing olaparib 
or camptothecin, in the presence or absence of BI2536. Mitotic cells 
were collected and spread to analyze the accumulation of chromo-
some breaks. As observed previously, cells expressing PrimPolS538A 
had an increased number of breaks under all conditions compared 
to PP cells or those expressing PrimPol (Fig. 5E and fig. S8B). The 
addition of the PLK1 inhibitor did not further increase chromo-
somal breaks in PrimPolS538A cells, nor did it increase the number of 
breaks in PP cells, suggesting that the inhibition of PLK1 alone did 
not induce breaks. However, breaks increased in cells expressing 
PrimPol to levels similar to PrimPolS538A cells. These findings suggest 
that preventing active phosphorylation of PrimPol by PLK1 is able 
to phenocopy the genotoxicity caused by the S538A mutation.
PrimPolS538A phenotypes are caused by its dysregulation 
across the cell cycle
As S538 phosphorylation is largely restricted to G2 and mitosis, 
PrimPolS538A expressed in these cell cycle stages may be a potential 
cause of genotoxicity. To investigate changes in genomic stability across 
different cell cycle stages, we examined the formation of micronuclei. 
Cells were first labeled with EdU (5-ethynyl-2′-deoxyuridine) to 
identify those in S phase and then immediately treated with 0 or 5 J/m2 
UV-C and allowed to recover for up to 48 hours. Cells expressing 
PrimPolS538A had a significantly higher percentage of EdU-positive 
cells with micronuclei, 48 hours after labeling, suggesting that they 
may be retained by the cell for longer. When UV-C–treated cells 
were analyzed, we observed that in PP-1 cells and those expressing 
PrimPol or PrimPolS538E, most micronuclei were found in cells that 
were in S phase when they were damaged (Fig. 6A and fig. S9A). 
EdU-negative cells, cells damaged by UV-C outside of S phase, 
showed little increase in micronuclei, even 48 hours after UV-C 
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Fig. 4. Mutation of PrimPol’s ZF reduces PrimPolS538A -induced genomic instability. (A) Damage sensitivity changes caused by the addition of the ZF mutations in 
PrimPol were measured by colony survival with increasing doses of UV-C, cisplatin, olaparib, and camptothecin. Cells with one or more chromosome breaks were counted 
96 hours after PrimPol expression (B) or after 48 hours of incubation with olaparib or camptothecin (C). (D) Micronuclei were counted 48 hours after recovery from 0 or 5 J/m2 
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major cause of micronuclei in PP-1 cells or those expressing 
PrimPol or PrimPolS538E. In contrast, cells expressing PrimPolS538A 
showed a significant increase in micronuclei, in both EdU-positive 
and EdU-negative cells. These data show that expression of 
PrimPolS538A after UV-C damage leads to micronuclei, regardless of 
whether the damage occurred in replicating or nonreplicating cells.
To examine changes in the recruitment of PrimPolS538A outside 
of S phase, we analyzed cell stage–specific chromatin binding. Cells 
were first synchronized using a double thymidine block and re-
leased to progress through the cell cycle before being treated with 
0 or 20 J/m2 UV-C. Cells were allowed to recover for 1 hour before 
chromatin isolation. UV-C damage induced an increase in chromatin- 
bound RPA2, and RPA2 phosphorylated at S33, an ATR-dependent 
modification induced by DNA damage (47). PrimPol bound to 
chromatin in G1 and S phases, with no observable binding in G2 
(Fig. 6B and fig. S9B) (42). However, 1 hour after 20 J/m2 UV-C 
damage, PrimPolS538A was found to be chromatin associated in G2, 
while PrimPol and PrimPolS538E were not observably recruited 
(Fig. 6B). We also followed PrimPol’s chromatin dissociation across 
the cell cycle and found loss of chromatin binding as cells pro-
gressed into G2, which correlates with S538 phosphorylation changes 
described earlier (Fig. 5D and fig. S9C). Together, these data indi-
cate that S538 phosphorylation may play an important role in the 
regulation of PrimPol’s recruitment to chromatin.
In addition, we observed an increase in RPA foci in cells expressing 
PrimPolS538A under both undamaged and UV-C–treated conditions, 
suggesting a possible increase in ssDNA (Fig. 6C and fig. S9D). To look 
more closely at this, we analyzed levels of native CldU incorporated 
into DNA to look more specifically for ssDNA. We observed a minor 
increase in CldU signal in cells expressing mutant forms of PrimPol, 
and this was also seen with damage (Fig. 6D and fig. S9, E and F). 
However, this difference was decreased when cells were first treated 
with BI2536 to inhibit PLK1 with cells expressing PrimPol and 
PrimPolS538A showing little differences (Fig. 6D and fig. S9, E and F).
In addition, we assessed levels of ssDNA gaps during replication, 
using the S1 fiber assay to detect repriming events. Under asynchro-
nous conditions, we observed little differences between cell lines. 
However, when cells were synchronized to late S phase, we noted 
increased fiber shortening after S1 treatment in cells expressing 
PrimPolS538A, suggesting increased repriming (Fig. 6E). To look at 
the impact of PLK1 phosphorylation on late S phase repriming, we 
released cells from thymidine into BI2536 to prevent S538 phos-
phorylation. Cells were allowed to progress into late S phase, at 
which point we again measured S1 nuclease cutting. We found that 
all cell lines showed an increase in replication fork length distribu-
tion after PLK1 inhibition and that expression of PrimPol now also 
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Fig. 5. PrimPol S538 phosphorylation is cell cycle regulated by PLK1. (A) Alignment of the region of PrimPol containing a predicted PLK1 site (orange box) in different 
species, residue 538 in human protein. Hs, H. sapien (human); Tt, T. truncatus (Atlantic bottle-nosed dolphin); Ts, T. syrichta (Philippine tarsier); Hg, H. glaber (naked mole rat); 
Cp, C. porcellus (guinea pig). (B) In vitro PLK1 kinase assays where PrimPol or PrimPolS538A was incubated with recombinant PLK1 and the resulting protein phosphoryl ation 
analyzed by Western blotting. (C) HEK293 PP-1 cells expressing PrimPol were treated with BI2536 or mock treated (left). RPE1 PLK1-as cells expressing PrimPol were 
treated with 3-MB-PP1, and whole-cell lysate was subjected to Western blotting (right). (D) HEK293 PP-1 cells expressing PrimPol were released from a double thymidine 
block for increasing times or left untreated as an asynchronous control and analyzed for cell cycle synchronization by flow cytometry (bottom). Whole-cell extract from 
cells at each time point was subjected to Western blotting (top). (E) Chromosome breaks were analyzed after synchronization, and cells were released from a double 
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Phosphorylation of S538 is actively regulated in response 
to fork stalling
As well as cell cycle changes, PLK1 has previously been shown to 
regulate protein activity via phosphorylation in response to DNA 
damage (27, 28). We therefore analyzed whether PrimPol may also 
be regulated in response to damage/fork stalling by PLK1, through 
its phosphorylation of S538. When cells were allowed to progress 
synchronously through the cell cycle in the presence of damage, 
S538 phosphorylation was delayed along with the cell cycle, but 
phosphorylation was still detected once the bulk of cells entered G2 
(fig. S10, A and B). This confirmed that S538 phosphorylation is 
tightly maintained with cell cycle stage and constitutively activated 
upon completion of S phase.
To determine whether active dephosphorylation of S538 was 
possible in response to damage, we first synchronized cells to the 
G1-S boundary using thymidine and released synchronously for 
5 hours to late S phase, the point where S538 phosphorylation 
begins to appear. Cells were then treated with sufficient doses of 
UV-C, olaparib, or camptothecin to slow the S phase completion 
but still ultimately allow cells to progress to mitosis. We found a 
small but consistent decrease in phosphorylation shortly after 
damage, compared with unperturbed cells (Fig. 7A and fig. S10C). 
This was most prominent 1 hour after camptothecin treatment and, 
in all cases, was resolved around 5 hours after damage induction 
when most cells were in G2 or mitosis. However, flow cytometry- 
activated cell sorting (FACS) analysis revealed that 5  hours 
after release, a large proportion of cells had already entered G2 
and were therefore unlikely to encounter stalled replication 
forks. This suggested that we were unable to visualize damage- 
induced dephosphorylation because of increased phosphorylation 
in G2 cells.
To address this, we repeated the experiment with the addition 
of the PLK1 inhibitor BI2536, preventing further phosphorylation 
by PLK1. Cells were released from a thymidine block into late 
S phase as before, but this time, before damage, cells were treated 
with BI2536 and allowed to progress through the cell cycle for a 
further 5 hours, at which point most cells had reached mitosis 
(Fig. 7B). In the absence of BI2536, damaged cells showed a simi-
lar increase in phosphorylation to untreated cells (Fig.  7B). In 
contrast, where PLK1 was inhibited, no increase in phosphoryl-
ation was observed upon G2-M entry in the absence of damage. 
Notably, cells treated with olaparib, camptothecin, or UV-C showed 
a significant loss of S538 phosphorylation (Fig. 7B). This indicates 
that PrimPol is actively dephosphorylated in response to damage 
in late S phase. We hypothesize that this dephosphorylation is im-
portant for proper utilization of PrimPol in late S phase, where it 
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Fig. 6. Dysregulation of PrimPol across the cell cycle drives genotoxic phenotypes. (A) To quantify micronuclei in cells, they were first labeled with EdU to distinguish 
those in S phase. Cells were treated with 0 or 5 J/m2 UV-C and allowed to recover for 48 hours before being analyzed for micronuclei and EdU. (B) Cells were synchronized 
by double thymidine block and released into respective cell cycle stages before being UV-C damaged and allowed to recover for 1 hour. Chromatin fractions were then 
isolated and analyzed by Western blotting. (C) RPA2 foci were quantified in undamaged cells or 24 hours after UV-C treatment, representative images shown in fig. S9D. 
(D) Cells were labeled with CldU for 48 hours before being washed and left untreated or treated with 10 M olaparib for 2 hours. Cells were then stained for CldU under 
native conditions to analyze ssDNA. Images were quantified in ImageJ, n = 3 (olaparib, N = 2), examples shown in fig. S9F. (E) ssDNA gaps in newly replicated DNA, specifically 
in late S phase, were measured using the S1 fiber assay on cells synchronized with a double thymidine block. Cells were released for 6 hours with or without BI2536 and 
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DISCUSSION
PrimPol-dependent repriming offers many advantages as a mecha-
nism for restarting arrested forks. It enables stalled DNA synthesis 
to resume by bypassing a diverse range of impediments, without 
interacting with the obstacle itself, as occurs in TLS. In addition, 
when PrimPol mediates replication restart, it likely only incorpo-
rates a small number of nucleotides before disassociating, due to 
its low processivity, minimizing any mutagenic events. However, 
PrimPol-mediated repriming must be tightly regulated, as excessive 
repriming could lead to increased accumulation of ssDNA gaps that 
interfere with other key pathways, such as transcription and 
replication.
In this study, we establish that PrimPol is regulated by PLK1 
phosphorylation and that the levels of this modification change 
throughout the cell cycle (Fig. 5D). Phosphorylation increases as 
DNA replication is completed, coinciding with a suppression of 
PrimPol’s recruitment as cells progress into G2 (Fig. 6B). Preventing 
S538 phosphorylation leads to decreased survival after DNA damage 
or replication stress, an increase in genomic instability in both 
damaged and unperturbed cells (Figs. 2A and 3, A and B), and 
deregulated PrimPol recruitment outside of S phase. These pheno-
types can be entirely rescued by mutation of the RPA binding 
domains to prevent chromatin binding (Fig. 2, F and G) and partially 
rescued by mutations to the ZF domain (Fig. 4, A  to D). PLK1- 
dependent phosphorylation can also be delayed or removed when 
cells experience replication stress (Fig. 7, A and B). These findings 
support a model whereby PrimPol usage at stalled replication forks 
is dynamically regulated by phosphorylation (Fig. 7C). Together, 
these results highlight the importance of regulating repriming and 
maintaining a balance between the multiple DDT pathways.
Regulation of PrimPol by PLK1 alters pathway availability
The role of PLK1 as a highly conserved regulator of mitosis is well 
established (48). Outside of mitosis, PLK1 has been proposed to 
play roles in S phase, although recent evidence suggests that DNA 
replication itself suppresses PLK1 activity and its levels do not 
increase until the bulk of DNA synthesis is complete (25, 43, 48, 49). 
Phosphorylation of PrimPol by PLK1 closely aligns with this pro-
file. PrimPol displays low levels of S538 phosphorylation in early S 
phase and higher levels in late S-G2 (Fig. 5D). Phosphorylation at 
the end of S phase may potentially operate to keep PrimPol away 
from replication forks in common fragile sites, which are replicated 
in late S phase (50). Following a similar pattern, PLK1 has also been 
shown to phosphorylate BRCA2 as cells complete S phase, with 
phosphorylation levels peaking during mitosis (26). As with PrimPol, 
the cell cycle–dependent phosphorylation of BRCA2 can be sup-
pressed by the application of DNA-damaging agents.
As it has potentially genotoxic priming activity, the cell’s require-
ments for PrimPol are likely to significantly change throughout the 
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Fig. 7. S538 phosphorylation of PrimPol changes in response to DNA damage and cell cycle progression. (A) PrimPol S538 phosphorylation levels were followed 
after damage in late S phase. Cells were released from a double thymidine block into nocodazole containing media for 5 hours before the addition of damage and 
analyzed by Western blot. (B) Loss of PrimPol S538 phosphorylation was monitored, after late S phase damage, in the presence of the PLK1 inhibitor to prevent 
rephosphorylation. Cells were released from a double thymidine block into media containing nocodazole for 5 hours, before the addition of damage or no damage (ND) in 
the absence or presence of BI2536 for a further 5 hours. Whole-cell lysates were analyzed by Western blotting and progression into mitosis by P-H3 staining for flow 
cytometry. (C) A schematic model showing the levels of S538 phosphorylation during S-G2 and the proposed roles this plays in regulating PrimPol’s usage during the cell 
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PLK1 at the end of S phase negatively regulates PrimPol’s activities 
as cells enter G2. Loss of this regulation leads to inappropriate PrimPol 
usage outside of S phase. This likely leads to unscheduled repriming 
events causing increased ssDNA gaps that interfere with G2 pathways, 
as well as at transcription bubbles. Cell cycle–dependent phosphoryl-
ation provides an innate regulatory mechanism whereby proteins 
can be dynamically and reversibly regulated, without the need to be 
degraded and resynthesized. Our study has demonstrated that 
although PrimPol is gradually repressed toward the end of S phase, 
if cells experience significant replication stress in late S phase, then 
PrimPol can be reactivated by dephosphorylation (Fig. 7C). This 
implies the usage of one or more phosphatases working in concert 
with PLK1 to regulate PrimPol, although more work is required to 
uncover this regulatory mechanism.
The outcomes of dysregulation of the PrimPol pathway
Cells expressing PrimPolS538A, which cannot be phosphorylated, are 
sensitive to olaparib, camptothecin, UV-C, and cisplatin (Figs. 2A 
and 3A). These treatments induce replication stress, which leads to 
fork stalling and the generation of ssDNA. ssDNA is particularly 
sensitive to damage and hypermutation, due to greater expo-
sure of the bases to oxidative and chemical damage (51). There-
fore, ssDNA is bound by RPA for protection during replication 
and repair. Without regulation, PrimPol may be aberrantly recruit-
ed to these regions of ssDNA through its interaction with RPA, 
when alternative mechanisms of DDT may be better suited. As a 
result, an increase in ssDNA is observed in PrimPolS538A cells 
(Fig. 6, C to E).
A recent study indicated that the ssDNA gaps left behind by 
PrimPol-mediated repriming are repaired by Rad51-dependent HR 
pathways (52). To maintain cell survival and suppress DSB forma-
tion, ssDNA gaps must be repaired before the cell progresses 
through the cell cycle, and a marked increase in gaps is likely to 
require much of the cell’s HR machinery. In addition, excess ssDNA 
may potentially deplete the cell’s RPA pool, leaving ssDNA exposed 
and sensitive to further damage, ultimately leading to replication 
catastrophe (16, 53, 54). Recent work has also suggested that cancer 
cell survival depends, in part, on a shift in the balance between DDT 
pathways, with cancer cells increasingly dependent on TLS poly-
merases to suppress excessive ssDNA gap formation (55). This 
recent study lends support to a hypothesis that deregulation of 
PrimPol leads to increased recruitment in late S-G2, leading to 
increased gap formation and decreased cell fitness and genomic 
stability.
In addition to DNA-damaging agents, loss of PrimPol regulation 
also causes sensitivity to the PARP inhibitor olaparib. PARP plays 
multiple roles in the maintenance of genomic stability, including 
repair of SSBs and unligated Okazaki fragments, as well as promot-
ing replication fork reversal (33, 36, 56). It has been reported that 
PARP1 acts in conjunction with CARM1 to promote fork reversal, 
and its inhibition by olaparib leads to increased utilization of PrimPol 
(15). Our findings also show that replication fork speeds increased 
after olaparib treatment, although notably, this was not increased 
further in PrimPolS538A cells. We observed similar sensitives with 
camptothecin but have shown that all mutants are able to reinitiate 
replication after stalling in S phase. This suggests that regulation of 
PrimPol by PLK1-dependent phosphorylation is less important in 
S phase and mainly acts to regulate PrimPol once the bulk of repli-
cation is completed.
PrimPolS538A phenotypes require RPA binding but are only 
partially dependent on the ZF
Although we show that phosphorylation of PrimPol regulates its 
activities throughout the cell cycle, the details of how this is achieved 
are still to be determined. The location of this PLK1 modification 
between the RBMs initially implied that S538 phosphorylation may 
regulate PrimPol’s RPA interaction. However, we observed no differ-
ence in the interaction of PrimPolS538A or PrimPolS538E with chromatin 
or with RPA70 in vivo or in vitro. However, PrimPol’s interactions 
with RPA at stalled forks may be dependent on other modifications or 
binding partners that are yet to be uncovered. Genomic instability 
phenotypes induced by PrimPolS538A expression are, however, de-
pendent on RPA binding and recruitment to chromatin (Fig. 2F).
While PrimPolZF mutant cannot initiate de novo primer synthe-
sis, it retains polymerase activity and can extend existing primers 
(7, 37). Most of the PrimPolS538A genotoxicity was lost by mutating 
the ZF domain. These cells showed increased survival after genotoxic 
stress and decreased chromosome breaks compared to PrimPolS538A 
alone. This aligns with observations from other in vivo complemen-
tation studies, where it has been found that most phenotypes 
observed upon PrimPol depletion are not complemented by PrimPolZF 
(4,  7,  57). These data suggest that PrimPolS538A genotoxicity is 
largely due to PrimPol’s repriming activity. However, cells express-
ing PrimPolZF,S538A are still more damage sensitive than PrimPolZF 
(Fig. 4). We hypothesize that this is likely to be due to the aberrant 
recruitment of PrimPolS538A to chromatin, which is maintained after 
the addition of the ZF mutations (fig. S7F). Aberrant recruitment, 
without the ability to reprime, may block alternative mechanisms of 
DDT or repair and delay fork restart, leading to this partial phenotype.
In summary, this study establishes that PLK1-dependent 
phosphorylation of PrimPol prevents aberrant recruitment and 
repriming that could otherwise lead to significant genomic instability. 
Our data highlight the importance of appropriately regulating 
PrimPol’s recruitment following replication fork stalling and through-
out the cell cycle. While this study identifies that PrimPol is specifi-
cally regulated by PLK1, it is likely that additional mechanisms also 
regulate PrimPol and other DDT pathways to ensure that cells 
respond appropriately in the immediate aftermath of replication 
stress. The discovery of PLK1’s role in regulating PrimPol’s deploy-
ment highlights other important functions that this major cell cycle 
kinase undertakes outside of mitosis, including acting as key 
regulator of genome stability.
MATERIALS AND METHODS
In vitro kinase assay
To confirm PLK1 phosphorylation of PrimPol, 1 g of purified PrimPol 
(WT or S538A) was incubated in a 20-l reaction with NEB protein 
kinase buffer, 500 M ATP, and 20 g of PLK1 (Merck). The 
reaction was incubated at 30°C for 2 hours before addition of Laemmli 
sample buffer and boiling. Samples were then analyzed by Western 
blot with a total PrimPol and P-S538–specific antibodies.
Plasmids and mutagenesis
pCDNA5 containing N-terminally Flag-tagged PrimPol was used 
to express PrimPol in HEK293 cells as described previously (30). 
PrimPol was cloned into the Sleeping Beauty plasmid pSBtet following 
polymerase chain reaction (PCR) amplification with primers 
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England Biolabs) (31). A range of mutants were generated by site- 
directed mutagenesis as described previously (6,  7,  30); briefly, 
PCR was carried out with Phusion (New England Biolabs) along 
with the relevant primers described in table S1, and products were 
transformed into Escherichia coli. Plasmids were purified, and the 
generation of the desired mutation was confirmed by Sanger se-
quencing (GATC).
Human cell culture
HEK293 cells were grown at 37°C, 5% CO2 in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum, 
1% l-glutamine, and 1% penicillin/streptomycin. RPE1 cells were 
grown in DMEM/F12 supplemented with 10% fetal calf serum, 1% 
l-glutamine, and 1% penicillin/streptomycin.
To generate PrimPol knockout cell lines, guide oligos, 1 
(5′-TTATCATCCGTATACAGGCCAAGATTGTCCAAGC-
CAGAAGAACCAC-3′) or 2 (5′-CCATCTATATGGAGGCT-
GTTTCATCGACAAGCTCAAGCTTTTAATTTTG-3′) targeted 
to the first exon of PrimPol, were cloned into plasmid pSpCas9(BB) 
as described (58). These plasmids were transfected into Flp-In 
HEK293 T-REx cells, which were separated into single cells in 
96-well plates, 3 days after transfection, and grown to form single 
colonies. Single colonies were selected and expanded, and a propor-
tion were taken for PCR across the target region. PCR was carried 
out with primer sets KO1, across the guide targeted site, and KO2, 
far away in exon 7. Clones that showed a change in product size or 
loss of the target site product, while the exon 7 product was un-
changed, were expanded further and tested for loss of PrimPol by 
Western blotting with a PrimPol-specific antibody (12). The genetic 
change was also confirmed by sequencing of the PCR product 
generated across the deleted region.
To generate cell lines expressing mutant forms of PrimPol, 
Flp-In HEK293 T-Rex cells were cotransfected with pOG44 and 
pCDNA5 containing Flag-tagged PrimPol using calcium phosphate 
(59). Cells were selected with hygromycin (100 g/ml) and blasticidin 
(15 g/ml) for approximately 2 weeks, and the resulting resistant 
clones were pooled. PrimPol was then expressed in these cells by the 
addition of doxycycline (10 ng/ml). Growth rates of different cell 
lines were calculated in the presence of doxycycline (10 ng/ml) by 
counting cells at approximately 24-hour intervals using a hemocy-
tometer, and growth curves were then used to calculate the dou-
bling time using an online tool (60).
PLK1 disruption in vivo
To inhibit PLK1, 10 nM BI2536 (Merck) was added to cell media 
for 16 hours before protein induction by doxycycline (10 ng/ml). 
Phosphorylation of protein after BI2536 treatment was assessed by 
Western blot.
RPE1 PLK1-AS (42) cells were cotransfected with 2 g of pSBtet-­
PrimPol and 100 ng of transposase enzyme plasmid pSB-100X by 
electroporation and selected for 10 days using puromycin (2 g/ml). 
Clonal cell lines were generated from single cells and screened for 
incorporation of BFP (blue fluorescent protein). To inactive PLK1 in 
these cells, cells were treated with 1 M 3-MB-PP1, followed by 
induction of protein expression using doxycycline (100 ng/ml).
Western blotting and antibodies
To check protein expression, cells were induced by the addition of 
doxycycline (10 ng/ml) for 24 hours, and 30 g of total cell lysate 
was analyzed by Western blotting with a PrimPol antibody in 
comparison to -tubulin controls. To look specifically at PrimPol 
phosphorylation, a phospho-peptide antibody was generated 
(Eurogentec). Antibodies were raised in rabbits to the peptide 
ac- ELAEAAEN-S(PO3H2)-LLS+C –conh2 and affinity-purified. 
The specificity of the antibody was confirmed by Western blotting 
of phosphatase-treated cell lysate. Briefly, cells were lysed in radio-
immunoprecipitation assay (RIPA) buffer. Five microliters of PMP 
buffer (New England Biolabs) and MnCl2 (New England Biolabs) 
was then added to 40 l of protein sample and then incubated at 
30°C for 1 hour with or without 400 U of  phosphatase. The speci-
ficity of the antibody was assessed by Western blot.
Immunoprecipitation
PrimPol was isolated from HEK293 cells as described previously 
(29). Briefly, approximately 1 × 107 cells expressing Flag-tagged 
PrimPol were lysed in NETN buffer [150 mM NaCl, 30 mM tris 
(pH 7.5), 0.5% NP-40, 2.5 mM MgCl2, and deoxyribonuclease I 
(100 g/ml)] for 30 min at 4°C. Cell lysate was incubated with 
Anti-Flag M2 magnetic beads (Merck) for 2 hours at 4°C before 
beads were washed three times with wash buffer [150 mM NaCl, 
30 mM tris (pH 7.5), and 0.1% NP-40]. Proteins and interacting 
partners were eluted with 50 l of elution buffer [25 mM tris-HCl 
(pH 7.5), 150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride, and 
3xFLAG peptide (200 g/ml; Merck)] and analyzed against input 
cell lysate by Western blot.
For mass spectrometry analysis, 10 × 107 cells expressing 
Flag-tagged PrimPol were lysed in RIPA buffer. Protein was bound 
by Anti-Flag M2 magnetic beads (Merck) for 2 hours at 4°C before 
being washed three times in 50 mM ammonium bicarbonate. After 
overnight on-bead digestion at 37°C by Glu-C protease, the pep-
tides were analyzed on an Orbitrap Exploris 480 [with FAIMS 
(Field asymmetric Ion mobility spectrometry)] mass spectrometer 
by the Proteomics Core Facility at CEITEC (Brno, Czech Republic).
Analysis of Xenopus PrimPol C-terminal domain
The X. laevis PrimPol C-terminal domain (CTD) sequence (amino 
acids 510 to 675) was gene synthesized (Eurofins) and cloned into 
the glutathione S-transferase expression vector pGEX-KGH. The 
protein was expressed in BL21 E. coli and purified on glutathione 
agarose (Sigma-Aldrich). Purified protein was dialysed into XB buffer 
and incubated with Xenopus egg extract treated with aphidicolin 
(100 g/ml). Sperm pronuclei were added (5 × 103/ml of extract) 
and incubated at 21°C for 80 min. Extract and nuclei were diluted 
with XB buffer containing 0.25% Triton X-100, and chromatin was 
recovered by centrifugation through 30% sucrose. The chromatin 
pellet was washed extensively with XB buffer and resuspended in 
XB buffer containing benzonase (2 U/l). Insoluble material was 
pelleted by centrifugation, and the soluble supernatant was applied 
to glutathione agarose beads. Protein was separated by SDS–
polyacrylamide gel electrophoresis and in-gel digested with trypsin 
and chymotrypsin (Promega) overnight at 37°C before analysis by 
mass spectrometry (LTQ Orbitrap XL/ETD).
Cell synchronization
To analyze cells within a specific cell cycle stage, cells were synchro-
nized with a double thymidine block. Cells were treated with 4 mM 
thymidine for 16 hours before being washed three times in phosphate- 
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cycling for 8 hours. Cells were then blocked again with 4 mM 
thymidine for 16 hours, and cells were washed three times in PBS 
and then used immediately at G1/early S phase or allowed to prog-
ress through the cell cycle in standard media for 2 hours, S phase, 
6 hours, G2, or 14 hours, G1. To analyze the effects of damage on 
phosphorylation, cells were released into media containing 1 M 
nocodazole to prevent them from progressing through to the next 
round of the cell cycle. Cells were then treated at relevant time 
points with 10 M olaparib, 50 nM camptothecin, or 20 J/m2 UV-C, 
and samples were later collected at relevant time points for chromo-
some spreads, protein, or FACS analysis. BI2536 (100 nM) was used 
to examine the effect of PLK1 inhibition.
Where PrimPol expression was required, doxycycline (10 ng/ml) 
was included in the media throughout. Cells treated in parallel were 
tested by flow cytometry to confirm synchronization and cell 
populations.
Plating efficiency and colony survival assays
Two hundred cells or a serial expansion dependent on expected 
toxicity were plated with the addition of doxycycline (10 ng/ml) if 
protein expression was required and allowed to attach for approxi-
mately 16 hours. Cells were then left untreated to analyze plating 
efficiency or treated with increasing doses of UV-C using a G6T5 
Germicidal 9” 6W T5 UV-C lamp (General Lamps Ltd.), or relevant 
concentrations of drugs were added. In the case of cisplatin, drugs 
were washed off after 6 hours. Colonies were allowed to form for 
approximately 10 days, and cells were stained with 1% methylene 
blue for counting. Sensitivity was measured in relation to plating 
efficiency calculated from undamaged controls.
Chromatin binding analysis
DNA bound protein populations were analyzed by chromatin assay 
as described previously (6). Approximately 7 × 106 cells were grown 
in doxycycline (10 ng/ml) for at least 16 hours before being treated 
with 0 or 20 J/m2 UV-C and allowed to recover for 6 hours. Cells 
were collected, and a quarter were resuspended in 50 l of NETN 
buffer [150 mM NaCl, 5 mM EDTA, 50 mM tris (pH 7.5), and 0.5% 
NP-40]. The remaining cells were incubated in 150 l of CSK buffer 
[100 mM NaCl, 300 mM sucrose, 3 mM MgCl2, 10 mM Pipes (pH 6.8), 
1 mM EGTA, and 0.2% (v/v) Triton X-100] on ice for 5 min before 
being pelleted at 4°C with the supernatant containing soluble pro-
teins. The pellet containing chromatin-bound proteins was washed 
twice in PBS and resuspended in Laemmli sample buffer and boiled 
for 10 min. Proteins were analyzed by Western blotting relative to 
whole-cell fraction using antibodies.
RPA foci
Cells were plated on poly-lysine–coated coverslips in doxycycline 
(10 ng/ml) for at least 16 hours. Cells were either left undamaged or 
treated with 6 J/m2 UV-C and allowed to recover for 24 hours. Cells 
were preextracted with CSK buffer [100 mM NaCl, 300 mM sucrose, 
3 mM MgCl2, 10 mM Pipes (pH 6.8), 1 mM EGTA, and 0.2% (v/v) 
Triton X-100] for 10 min on ice before being fixed with 3% para-
formaldehyde. Cells were stained with the relevant antibodies, mouse 
anti-RPA2 and anti-mouse Alexa Fluor 488, EdU was labeled by 
click chemistry, and slides were mounted in VECTASHIELD with 
4′,6-diamidino-2-phenylindole (DAPI) (Vector Labs) (table S2). 
Slides were analyzed on an Olympus IX70 fluorescent microscope 
and analyzed using ImageJ.
ssDNA staining
Cells were plated on poly-lysine–coated coverslips in doxycycline 
(10 ng/ml) and 10 M CldU for 48 hours. Cells were washed before 
being labeled with 10 M Edu in the absence or presence of 10 M 
olaparib or 50 nM camptothecin for 2 hours. Where PLK1 inhibi-
tion was required, cells were treated with 100 nM BI2536 for 1 hour 
before any damage, and BI2536 was maintained throughout. Cells 
were preextracted with 2× CSK buffer [100 mM NaCl, 300 mM 
sucrose, 3 mM MgCl2, 10 mM Pipes (pH 6.8), 1 mM EGTA, and 
0.4% (v/v) Triton X-100] for 10 min on ice before being fixed with 
3% paraformaldehyde. Cells were stained with the relevant antibodies, 
rat anti-BrdU and anti-rat Alexa Fluor 488, before click chemistry 
was used to label EdU, and slides were mounted in VECTASHIELD 
with DAPI (table S2). Slides were analyzed on an Olympus IX70 
fluorescent microscope and analyzed using ImageJ.
Micronuclei assays
To analyze micronuclei, cells were plated in doxycycline (10 ng/ml) 
for 16 hours before being treated with 0 or 5 J/m2 UV-C, 0.5 M 
olaparib, or 10 nM camptothecin. Forty-eight hours after treatment, 
cells were cytospun onto glass slides, fixed with paraformaldehyde, 
and mounted in VECTASHIELD with DAPI (Vector Labs). Cells 
were analyzed for the presence of micronuclei on a Nikon E400 
fluorescent microscope. To analyze the effect of cell cycle position 
at the time of damage, cells were plated overnight as before in 
doxycycline. They were then labeled with 10 M EdU for 30 min 
before being treated with 0 or 5 J/m2 UV-C. Cells were either 
collected immediately or allowed to recover for 24 or 48 hours before 
being cytospun and fixed in paraformaldehyde. EdU incorporation 
was labeled using the click-it reaction using sulfo-CY5 azide (Jena 
Biosciences) as described previously (12, 61).
Chromosome spreads
To analyze the occurrence of chromosome breaks, cells were first 
grown for 96 hours in the presence of doxycycline (10 ng/ml) alone or 
48 hours with 0.5 M olaparib or 10 nM camptothecin. Nocodazole 
(1 M) was added for the final 16 hours before the cells, now largely 
stalled in mitosis, were collected. Cells were swollen in 75 mM KCl 
at 37°C before being fixed in 3:1 methanol:acetic acid. Cells were 
dropped onto glass slides, and after drying, chromosomes were stained 
with Giemsa (Merck) and mounted in Eukitt Quick-hardening 
mounting medium (Merck). Slides were analyzed on a Nikon E400 
fluorescent microscope.
To look in more detail at chromosomal alterations, SCEs were 
analyzed as described previously (62). Briefly, cells were grown in 
doxycycline (10 ng/ml) and 10 M BrdU for 48 hours. Cells were 
blocked in mitosis and collected, spread, and dried as described 
above. Chromosomes were then stained with Hoechst (10 g/ml) 
before being washed in SSC (150 mM sodium chloride and 15 mM 
sodium citrate), exposed to UV light for 1 hour, and then incubated 
in SSC buffer for a further 1 hour at 60°C. Slides were then stained 
with Giemsa and mounted and viewed as described above.
Fiber assays
Replication fork speed and stalling were analyzed on DNA fibers as 
described previously (6). Briefly, approximately 10 × 104 cells were 
incubated in doxycycline (10 ng/ml) for at least 16 hours, and cells 
were then labeled with 25 M CldU for 20 min followed by 250 M 










Bailey et al., Sci. Adv. 7, eabh1004 (2021)     3 December 2021
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
13 of 15
UV-C was given in between the two labels. Where the effects of 
damage were analyzed, cells were either first treated with 10 M 
olaparib for 2 hours and throughout the labeling or 50 nM campto-
thecin was added along with IdU label. For analyses of fork restart, 
cells were labeled as normal with 25 M CldU for 20 min before the 
addition of 4 mM HU for 16 hours or 5 M camptothecin for 1 hour. 
Drugs were washed off, and cells were released into media contain-
ing 250 M IdU for 60 min. Cells were collected into 150 l of PBS, 
and 2.5 l was lysed directly on slides with 7.5 l of lysis buffer 
[20 mM tris (pH 7.5), 50 mM EDTA, and 0.5% SDS]. DNA was 
spread down the slides using gravity before being fixed with 3:1 
methanol:acetic acid. After rehydration, fibers were stained with 
antibodies to the specific labels, rat anti-BrdU [BU1/75 (ICR1)], 
mouse anti-BrdU clone B44, anti-rat Alexa Fluor 488, and anti- mouse 
Alexa Fluor 594 (table S2). Slides were mounted with Fluoromount 
(Sigma-Aldrich) and imaged on an Olympus IX70 fluorescent micro-
scope and analyzed using OMERO. The S1 fiber assay was adapted 
from previous protocols (63), and cells were labeled as above before 
being collected and treated with CSK buffer on ice for 10 min. 
Nuclei were pelleted and treated with 0 or 20 U/ml of S1 (Promega) 
for 30 min at 37°C before being washed and spread as above.
Flow cytometry
Cell cycle populations were analyzed using flow cytometry. To con-
firm synchronization, cells were collected at desired time points and 
fixed in 70% ethanol at −20°C. To label replicating DNA, cells were 
treated with 10 M EdU before collection. EdU-positive cells were 
then labeled using Click chemistry and sulfo-CY5 azide (Jena 
Biosciences) (12, 61). Cells were then washed in PBS and labeled 
with propidium iodide (PI; 5 g/ml), and RNA was degraded with 
ribonuclease A (150 g/ml). To follow progression into mitosis, 
samples were additionally stained for P-H3. After fixation, cells 
were permeabilized with 0.2% Triton X-100 in PBS for 10 min before 
blocking in 3% bovine serum albumin and staining with antibodies 
to P-H3 followed by anti-rat 488 green (table S2). Cells were then 
stained for EdU and PI as above. Samples were analyzed using a BD 
Accuri C6 flow cytometer, and approximately 10,000 cells were 
quantified using BD CSampler Software. To follow cell cycle pro-
gression after damage, cells were first plated in doxycycline (10 ng/ml) 
for at least 16 hours before being treated with 0 or 5 J/m2 UV-C. Cells 
were allowed to recover for increasing times before being labeled 
with 10 M EdU for 30 min and collected as above.
Purification of recombinant proteins
Full-length human PrimPol and S538A/E mutants were purified as 
described previously (7). Briefly, the proteins were expressed in 
SHuffle T7 E. coli cells (New England Biolabs) overnight at 16°C. 
Following sonication and isolation by centrifugation, the proteins 
were purified by affinity chromatography using Ni-NTA affinity 
resin (Generon), then separated by charge by affinity exchange 
chromatography on a Hi-Trap Heparin HP column (GE Healthcare), 
and lastly subjected to size exclusion chromatography on a Superdex 
75 gel filtration column (GE Healthcare).
PrimPol CTD (PrimPol480–560) and corresponding S538A/E 
mutants were purified as described previously (30). Briefly, the 
proteins were expressed in BL21 E. coli cells overnight at 20°C. Fol-
lowing sonication and isolation by centrifugation, the proteins were 
purified by affinity chromatography using Ni-NTA affinity resin 
(Generon), followed by separation by Q-Sepharose (GE Healthcare) 
and size exclusion chromatography on a Superdex 75 gel filtration 
column (GE Healthcare).
RPA70N (RPA701–120) was purified as described previously (30). 
Briefly, the protein was expressed in BL21 E. coli cells overnight at 
20°C. Following sonication and isolation by centrifugation, 
RPA70N was purified using Ni-NTA affinity resin (Generon) with 
a gradient elution. The polyhistidine tag was cleaved by thrombin 
overnight at room temperature, and the product passed through 
Ni-NTA affinity resin (Generon) to separate the protein from the tag. 
Last, the protein was separated by a size exclusion chromatography 
step on a Superdex 75 gel filtration column (GE Healthcare).
Analytical size exclusion chromatography
Protein interactions were analyzed by analytical size exclusion 
chromatography as described previously (29). Briefly, a Superdex 
75 10/300 GL gel filtration column (GE Healthcare) was preequilib-
riated in a buffer containing 50 mM tris-HCl, 100 mM NaCl, and 
2 mM TCEP (Tris(2-carboxyethyl)phosphine hydrochloride). First, 
individual proteins were loaded at a concentration of 35 M to pro-
vide baseline elution volumes for each. To test protein interactions, 
the CTD variants were mixed with RPA70N at 35 M. Interactions 
were identified by a shift in the chromatograph peaks relative to the 
respective baseline elution volumes.
Primase assays
Increasing concentrations of protein (0.5, 1, 2, and 4 M) were 
incubated in 20-l reactions containing 10 M ssDNA template 
(Cy5-CCAACCTTTATATTGCCAATCTCTAACCTTTTTC-
CCATTTACATATAGTddG) with 100 M deoxynucleotide triphos-
phates (dNTPs), 2.5 M FAM-y-GTP, 10 mM bis-tris-propane-HCl 
(pH 7), 10 mM NaCl, 2 mM MnCl2, and 0.5 mM TCEP. The 
reaction was carried out at 37°C for 30 min and stopped by the 
addition of 15 l of stop buffer (60% formamide, 5 mM EDTA, 
0.025% SDS, 0.09% xylene cyanol, and 6 M urea). Excess labeled NTP 
was removed by ethanol precipitation. Primers were resuspended in 
20 l of loading dye (95% formamide with 0.25% bromophenol blue 
and xylene cyanol). Samples were boiled and resolved on a 20% 
polyacrylamide/7 M urea/TBE gel at 25 W for 2 hours. Fluorescently 
labeled primers were detected using a Fujifilm FLA-5100 image reader.
Polymerase assays
A template oligonucleotide (GACTACTATCTCGACTATATAC-
TATTG CTTCTACGAAGACCTTCA) was annealed to a complemen-
tary fluorescently labeled DNA primer (FAM-TGAAGGT- 
CTTCGTAGAAGC). Protein (50 nM) was incubated with 30 nM 
annealed primer-template substrate, 10 mM bis-tris-propane-HCl 
(pH 7), 10 mM MgCl2, 10 mM NaCl, 0.5 mM TCEP, and 100 M dNTPs 
to a final volume of 20 l. The reactions were performed at 37°C and 
stopped at 2, 5, 10, and 15 min by the addition of 20 l of stop buffer 
(60% formamide, 5 mM EDTA, 0.025% SDS, and 6 M urea). For fidelity 
assays, similar conditions were used, except for 20 nM primer- template 
substrate, 100 nM PrimPol, and 200 M dNTPs and a 30-min reaction 
time. Samples were boiled and resolved on a 15% polyacrylamide/ 
7 M urea/TBE gel at 25 W for 1.5 hours. Fluorescently labeled oligo-
nucleotides were detected using a Fujifilm FLA-5100 image reader.
Data analyses
Charts show independent experiments with error bars showing 
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experiments. Significance was determined using Student’s t test or 
Mann-Whitney for fibers and foci, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, 
and ****P ≤ 0.0001. For fiber experiments, the black line represents 
the mean of the data where approximately 300 fibers were measured 
across three independent experiments unless stated otherwise. For 
cell analysis, approximately 500 cells were counted per independent 
experiment, and for chromosome spreads, this was 100 or 300 for 
SCEs. Data analysis was carried out using GraphPad, and images 
were quantified with ImageJ and OMERO.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at https://science.org/doi/10.1126/
sciadv.abh1004
View/request a protocol for this paper from Bio-protocol.
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